ED STATES PATENT AND TRADEMARK OFFICE

In re

Patent Application of

Rodney A. Welch, et al.

Serial No. 10 002,309

Filed: October 26, 2001

Examiner:

"E. COLI 0157 :H7 C1 ESTERASE INHIBITOR-BINDING PROTEIN AND METHODS OF USE" I, Leslie Lindsay, hereby certify that this correspondence is being deposited with the US Postal Service as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231, on the date of my signature.

Signature

January 28, 2002

Date of Signature

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 CFR §1.97(b)

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In compliance with the requirements of 37 CFR §§ 1.97-1.98 and pursuant to the duty of disclosure of 37 CFR § 1.56, Applicants wish to draw the Examiner's attention to the documents listed on accompanying Form PTO-1449. A copy of each listed document is enclosed.

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office Action on the merits, whichever event occurs last. 37 CFR 1.97(b).

Respectfully submitted,

Reg. No. 42,518

File No. 96429-9117

Michael Best & Friedrich LLP One South Pinckney Street P. O. Box 1806 Madison, WI 53701-1806 (608) 257-3501 In resolution of In The United States Patent and Trademark Office Group Art Unit

In resolution of I, Leslie Lindsay, hereby certify that this correspondence is being deposited with the US Postal Service as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231, on the date of my signature.

Serial No. 10/002,309

January 28, 2002

Date of Signature

Examiner:

"E. COLI O157 :H7 C1 ESTERASE INHIBITOR-BINDING PROTEIN AND METHODS OF USE"

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 CFR 1.97-1.98 WITHIN THREE MONTHS OF FILING OR BEFORE MAILING DATE OF FIRST OFFICE ACTION

Assistant Commissioner for Patents Washington, DC 20231

Sirs:

Pursuant to 37 CFR 1.97-1.98, Applicants submit a listing of documents on Form PTO-1449. A copy of each listed document is enclosed.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicants do not waive any rights to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

This information disclosure statement is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office Action on the merits whichever event occurs last. 37 CFR 1.97(b).

Applicants respectfully request that the listed documents be considered by the Examiner, be made of record in the present application and that an initialed copy of Form PTO-1449 be returned in accordance with MPEP § 609.

Respectfully submitted,

Hil A. Fahrlander Reg. No. 42,518

File No. 96429-9117

Michael Best & Friedrich LLP One South Pinckney Street P. O. Box 1806 Madison, WI 53701-1806 (608) 257-3501 FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-92) PATENT AND TRADEMARK OFFICE ATTY. DOCKET NO.:

096429/9117

INFORMATION DISCLOSURE

SERIAL NO.:

10/002,309

STATEMENT BY APPLICANT:

APPLICANT:

Welch et al

Use several sheets if necessary)

FILING DATE:

October 26, 2001

GROUP:

U.S. PATENT DOCUMENTS									
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIAT		
	T			-	1 627.55	GUBELASS	II AITKOPKIAT		
			CODETON	DATES IN DOCK	A A E NITTO				
	T	l	OKEIGN	PATENT DOCU	MENTS				
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES N		
	OTI	TED DOCED CEN	700 (T)		_				
		Dama N. T. D	TS (Includ	ling Author, Title	, Date, Per	tinent Pages	, Etc.)		
	AA	Perna, N. T., Plunkett III, G., Burland, V., Mau, B., Glasner, J. D., Rose, D. J. Kirkpatrick, H. A., Postal, G., Hackett, J., Klink, S., Boutin, A., Shao, Y., Miller, L., Grotbeck, E. J., Davis, N. W., Lim, A., Dimalanta, E. T., Potamousis, K. D., Apodaca, J., Anantharaman, T. S., Lin, J., Yen, G., Schwartz, D. C. Welch, R. A. & Blattner, F. P. (2001) Nature 400, 520, 523							
	AB	Schwartz, D. C., Welch, R. A. & Blattner, F. R. (2001) Nature 409, 529-533.							
	. 12	Waytes, A. T., Rosen, F. S. & Frank, M. M. (1996) N. Engl. J. Med. 334, 1630-1634.							
	AC	Caliezi, C., Wuillemin, W. A., Zeerleder, S., Redondo, M., Eisele, B. & Hack							
		C. E. (2000) Pharmacol. Rev. 52, 91-112.							
	AD				urnouf T	(1994) <i>Bloo</i>	d Coagulatio		
		Poulle, M., Burnouf-Radosevich, M. & Burnouf, T. (1994) <i>Blood Coagulation & Fibrinolysis</i> 5, 543-9.							
	AE			& Matsushima.	K. (1999) J	ournal of R	iological		
		Kuno, K., Terashima, Y. & Matsushima, K. (1999) Journal of Biological Chemistry 274, 18821-6.							
	AF	Gadek, J. E., H	osea, S. W	J., Gelfand, J. A.	, Santaella,	M., Wicke	rhauser, M.,		
		Gadek, J. E., Hosea, S. W., Gelfand, J. A., Santaella, M., Wickerhauser, M., Triantaphyllopoulos, D. C. & Frank, M. M. (1980) N. Engl. J. Med. 302, 542-							
		546.	•						
	AG	De Lorenzo, V	. D. & Tin	nmis, K. N. (1994	4) in Bacte.	rial Pathogo	enesis, eds.		
		Clark, V. L. & Bavoil, P. M. (Academic Press, San Diego), Vol. 235, pp. 386-							
		405.							
	AH	O'Farrell, P. H. (1975) J Biol Chem 250, 4007-21.							
	AI	Bauer, M. E. & Welch, R. A. (1996) Infect. Immun. 64, 167-175.							
	AJ	Burland, V., Shao, Y., Perna, N. T., Plunkett, G., Sofia, H. J. & Blattner, F. R.							
	1.75	(1998) Nucleic Acids Research 26, 4196-4204. Roesch, P. L. & Blomfield, I. C. (1998) Molecular Microbiology 27, 751-61.							
	AK								
	AL	Catanese, J. &	Kress, L. I	F. (1984) Biochin	n. Biophys.	Acta 789, 3	37-43.		

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-92) PATENT AND TRADEMARK OFFICE

NFORMATION DISCLOSURE STATEMENT BY APPLICANT:

several sheets if necessary)

COMMERCE ATTY. DOCKET NO.:

096429/9117

SERIAL NO.:

10/002,309

APPLICANT:

__ _

ALI LICANI.

Welch et al

FILING DATE:

October 26, 2001

GROUP:

AM	Karmali, M. A., Petric, M., Steele, B. T. & Lim, C. (1983) Lancet 1, 619-620.
AN	Caprioli, A., Luzzi, I., Gianviti, A., Russmann, H. & Karch, H. (1995) J. Med.
	Microbiol. 43, 348-353.
AO	Jiang, W. & Bond, J. S. (1992) FEBS Lett 312, 110-114.
AP	Jung, CM., Matsushita, O., Katayama, S., Minami, J., Sakurai, J. & Okabe,
	A. (1999) J. Bact. 181, 2816-2822.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.